Article Text

Download PDFPDF
A web-based clinical prediction tool predicted 10 year survival in breast cancer

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In women with stage I or II breast cancer, does the Adjuvant! web-based clinical prediction tool predict prognosis with and without adjuvant systemic therapy in terms of overall survival (OS), breast cancer specific survival (BCSS), and event free survival (EFS)?

Clinical impact ratings Oncology ★★★★★★☆


Embedded ImageDesign:

validation of a previously developed clinical prediction guide.

Embedded ImageSetting:

British Columbia, Canada.

Embedded ImagePatients:

4083 women with non-metastatic, stage I–II breast cancer diagnosed between 1989 and 1993. Exclusion criteria were male sex, age <20 or >85 years, incomplete local therapy, unknown tumour or nodal status, previous or synchronous contralateral breast cancer, or referral at relapse or <10 years of follow up.

Embedded ImageDescription of prediction guide:

Adjuvant! ( contains 10 year observed OS for women 36–69 years of age diagnosed with breast cancer between 1988 and 1992 in the US and entered in the Surveillance, Epidemiology and End Results (SEER) registry. BCSS and EFS were …

View Full Text


  • For correspondence: Dr I A Olivotto, BC Cancer Agency, Victoria, British Columbia, Canada. iolivott{at}

  • Sources of funding: Canadian Breast Cancer Research Alliance and Michael Smith Foundation for Health Research.